Melissa Lambeth Kemp received her B.S. in Nuclear Engineering from MIT and her Ph.D. in Bioengineering from University of Washington. Dr. Kemp joined the faculty at Georgia Tech in 2006 after completing postdoctoral training at MIT. Her expertise is in computational modeling of metabolism and signal transduction, as well as developing statistical modeling tools to examine network relationships in high-dimension datasets. One major aspect of her research program linking ROS – the byproducts of aerobic metabolism – to the fundamental way that cells interpret instructions from their environment, their neighbors, and their own genetic blueprint. Specific applications of her diverse work include systems modeling of transient phosphatase oxidation of kinase cascades, patient-specific differences in cytotoxicity to redox-cycled chemotherapeutics and radiation, and the coordination of oxidative metabolism with epithelial-to-mesenchymal transition. Her research program also includes a component of developing high-throughput screening methods for assaying cue-signal-response relationships in cells and analytical tools for single cell gene expression. 

Dr. Kemp currently serves as the Research Director of the multi-site NSF Engineering Research Center “Cell Manufacturing Technologies”. In her former role as Associate Director of the NSF Science and Technology Center “Emergent Behavior of Integrated Cellular Systems”, she spearheaded the multi-site center’s computational activities by developing agent-based models of context-dependent cellular decisions to generate new hypotheses of intercellular communication in pluripotent stem cell differentiation and emergent patterning; this work continues currently in quantifying organizational principles and spatial relationships in iPSC-derived tissues from multi-omics data. Dr. Kemp’s career honors include a Whitaker Graduate Fellowship, Merck/CSBi postdoctoral fellowship, Georgia Cancer Coalition Distinguished Scholar, NIH New Innovator Award, and the CSB2 Prize for Innovative Measurement Methods from the Council for Systems Biology in Boston.

Dr. Keilholz has been working in preclinical imaging for more than twenty years, with the goal of using animal models to improve the analysis of human MRI imaging. Her research uses multimodal approaches to extract information about neural dynamics from functional neuroimaging studies.

Yonggang Ke's research is highly interdisciplinary combining chemistry, biology, physics, material science, and engineering. The overall mission of his research is to use interdisciplinary research tools to program nucleic-acid-based "beautiful structures and smart devices" at nanoscale, and use them for scientific exploration and technological applications. Specifically, his team focuses on (1) developing new DNA self-assembly paradigms for constructing DNA nanostructures with greater structural complexity, and with controllable sizes and shapes; (2) developing new imaging or drug delivery systems based on DNA nanostructuresl; (3) exploring design of novel DNA-based nanodevices for understanding basic biological questions at molecular level; (4) developing DNA-templated protein devices for constructing artificial bio-reactors.

For cancer-related research/application, Ke will focus on using DNA/RNA nanostructures as drug delivery vehicles. He is also interested in using DNA/RNA nanostructures to study cancer cell biology at molecular level.

Dr. Hanjoong Jo is John and Jan Portman Professor in the Coulter Department of Biomedical Engineering (BME) at Georgia Tech and Emory University, and Professor of Medicine at Emory University. He is also the Associate Chair of Emory in BME Department. Upon graduation from Korea University, Dr. Jo received PhD under the co-mentorship of Professors John Tarbell (Chemical Engineering) and Ted Hollis (Physiology) at Pennsylvania State University in 1989. Following postdoctoral training in Jay McDonald Lab at Washington University in St. Louis and University of Alabama at Birmingham, he became Assistant Professor in Pathology and BME. Dr. Jo joined the BME Department at Georgia Tech and Emory University in 2000. He directs the Cardiovascular Mechanobiology and Nanomedicine lab. His lab studies how mechanical force associated with blood flow regulates vascular biology and cardiovascular disease, especially atherosclerosis, aortic valve (AV) calcification, and abdominal aortic aneurysms. He has published more than 150 peer-reviewed papers and edited two books. He developed the mouse model of atherosclerosis, known as partial carotid ligation model, induced by disturbed flow. His work led to the discovery of several genes (mechanosensitive genes and microRNAs) and epigenetic controlling mechanisms that are regulated by bad blood flow and play key roles in atherosclerosis and AAA. By targeting some of these mechanosensitive genes, his lab has been able to treat atherosclerosis and AAA in mice. His lab is now working on nanotechnologies to developing targeted gene and drug therapies in an effort to translate mouse studies toward clinical application. He is an elected fellow of American Institute of Medical and Biological Engineering, Biomedical Engineering Society, American Heart Association and American Physiological Society. He serves as associate editors and editorial board members of several cardiovascular and biomedical engineering journals including Scientific Reports, Circulation Research, Atherosclerosis Thrombosis Vascular Biology, Am J Physiology, Cell Molecular Bioengineering and Cardiovascular Engineering and Technology. He also has been serving as reviewers and chairs of study sections of the NIH, NSF, Veterans Administration and Am Heart Association. He also organized several international meetings, and in 2012, he served as the Chair of the Annual BME Society Meeting. He is also the founding President of Korean-American BME Society and Chairs of US-Korea Annual BMES Workshops since 2013. He has been a Distinguished Visiting Professor at Ewha Womans University and Chonbuk National University.

We strive to innovate in ways that both advance the imaging science and also impact biological and translational research. We are particularly interested in new imaging physics, bottom-up opto-electronic system design, as well as new principles for light propagation, light-matter interaction and image formation in complex biological materials, especially at the single-molecule level. Toward the application end, we have expertise in a wide range of imaging instrumentation and techniques, such as super-resolution, adaptive optics, light-field, miniaturized, light-sheet, computational microscopy and endoscopy.

I am the Patsy and Alan Dorris Chair of Pediatric Technology and Professor of Biomedical Engineering at the Georgia Institute of Technology. I also direct the Center for 3D Medical Fabrication (3DMedFab) and the Tissue Engineering and Mechanics Laboratory at Georgia Tech. We develop a range of 3D printed medical devices. We have over 25 devices implanted in patients for treatment of trachecobronchomalacia.

Many people are familiar with “genetics,” the inheritance of visible traits like eye and hair color. Traits are encoded by a molecular alphabet (A,T,C,G) in the well known double helix structure, DNA. Less well known, but quickly gaining attention, is the network of protein particles that interact with DNA to control the folding of chromosomes and the expression of inherited traits. This process is epi-genetics (epi, EH-pee = upon or above). Our research group uses gene and protein engineering to create new epigenetic machinery that regulates DNA at will. One day synthetic epigenetics may allow us to rationally design new biological systems with predictable, reliable behavior and replace “magic bullet medicine” with “smart medicine.”

We assemble interchangeable protein modules to build synthetic transcription factors that regulate gene activity in human cells. Unlike typical synthetic transcription factors that recognize specific DNA sequences, our Polycomb-based transcription factors (“PcTFs”) are engineered to read chromatin modifications. Thus, a single engineered TF could activate a group of silenced, therapeutic genes in cancer cells. Using strong gene activators could enhance cancer treatment and advance epigenetic medicine.

As synthetic biologists, our goal is to make the folded DNA-protein material, or chromatin (KRO-mah-tin = dark colored material in the nucleus of a fixed and stained cell), easier to design and engineer. Groups of genes often reside in the same compartments, and share the same DNA-protein packaging structures. Therefore, a small artificial change in one packaging protein can reprogram the expression of dozens, and even hundreds of genes. Is this outcome messy and useless, or is it a powerful mode of signal amplification that changes cells in useful ways? To answer this question, our group couples synthetic biology with bioinformatics by interrogating the expression of thousands of genes after we introduce artificial chromatin proteins into cells.

Bilal Haider is an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. He received B.S. and M.S. degrees from the University of Illinois Urbana-Champaign and M.Phil. and Ph.D. degrees from Yale University. He joined the faculty at Georgia Tech after completing postdoctoral training at University College London.

Haider’s research measures, manipulates and deciphers neural circuit activity underlying normal and impaired visual perception, providing new insights into how the brain processes information and orchestrates behavioral actions.

Haider has received several prestigious awards, including from the Whitehall Foundation, Simons Foundation and the Alfred P. Sloan Foundation. His work has been published in leading journals, including Nature, Nature Neuroscience, Nature Communications and Neuron.

Prof. Ethier was originally trained as a mechanical engineer, receiving his Ph.D. from MIT in 1986 working in the lab of Roger D. Kamm. He then joined the University of Toronto, where he was a Professor of Bioengineering, Mechanical Engineering and Ophthalmology, and latterly the Director of the Institute of Biomaterials and Biomedical Engineering. Prior to joining Georgia Tech/Emory, Professor Ethier was the Head of the Department of Bioengineering at Imperial College, London from 2007-12. 

His research is in the biomechanics of cells and whole organs. His specific research topics include glaucoma (biomechanics of aqueous humour drainage in the normal and glaucomatous eye, and the mechanical and cellular response of optic nerve tissues to intraocular pressure), study of hemodynamic basis of arterial disease.